Luminary Therapeutics clinical trials
The registry lists 6 studies whose lead sponsor is Luminary Therapeutics. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 18, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 6studies on the registry
- 6open to participants now
Get an email when these change. Save the Luminary Therapeutics studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now6100%Not yet recruiting 3 · Recruiting 3
Over the years
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Luminary Therapeutics.
- Luminary Therapeutics6 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 6 of 6.
- BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple MyelomaNot yet recruitingNCT07771361Phase 2
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune DiseaseNot yet recruitingNCT07729995Phase 1
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic MalignanciesNot yet recruitingNCT07679919Phase 1
- BAFF CAR-T Cells (LMY-920) for Systemic Lupus ErythematosusRecruitingNCT06340750Phase 1
- Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin LymphomaRecruitingNCT05312801Phase 1
- LMY-920 for Treatment of Relapsed or Refractory MyelomaRecruitingNCT05546723Phase 1